Stock Research for CNAT

CNAT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CNAT Stock Chart & Research Data

The CNAT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNAT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CNAT Due diligence Resources & Stock Charts

The CNAT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CNAT Detailed Price Forecast - CNN Money CNN View CNAT Detailed Summary - Google Finance
Yahoo View CNAT Detailed Summary - Yahoo! Finance Zacks View CNAT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CNAT Trends & Analysis - Trade-Ideas Barrons View CNAT Major Holders - Barrons
NASDAQ View CNAT Call Transcripts - NASDAQ Seeking View CNAT Breaking News & Analysis - Seeking Alpha
Spotlight View CNAT Annual Report - CompanySpotlight.com OTC Report View CNAT OTC Short Report - OTCShortReport.com
TradeKing View CNAT Fundamentals - TradeKing Charts View CNAT SEC Filings - Bar Chart
WSJ View Historical Prices for CNAT - The WSJ Morningstar View Performance/Total Return for CNAT - Morningstar
MarketWatch View the Analyst Estimates for CNAT - MarketWatch CNBC View the Earnings History for CNAT - CNBC
StockMarketWatch View the CNAT Earnings - StockMarketWatch MacroAxis View CNAT Buy or Sell Recommendations - MacroAxis
Bullish View the CNAT Bullish Patterns - American Bulls Short Pains View CNAT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CNAT Stock Mentions - StockTwits PennyStocks View CNAT Stock Mentions - PennyStockTweets
Twitter View CNAT Stock Mentions - Twitter Invest Hub View CNAT Investment Forum News - Investor Hub
Yahoo View CNAT Stock Mentions - Yahoo! Message Board Seeking Alpha View CNAT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CNAT - SECform4.com Insider Cow View Insider Transactions for CNAT - Insider Cow
CNBC View CNAT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CNAT - OTC Markets
Yahoo View Insider Transactions for CNAT - Yahoo! Finance NASDAQ View Institutional Holdings for CNAT - NASDAQ


Stock Charts

FinViz View CNAT Stock Insight & Charts - FinViz.com StockCharts View CNAT Investment Charts - StockCharts.com
BarChart View CNAT Stock Overview & Charts - BarChart Trading View View CNAT User Generated Charts - Trading View




Latest Financial News for CNAT


Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT
Posted on Thursday March 14, 2019

Q4 2018 Conatus Pharmaceuticals Inc Earnings Call


Implied Volatility Surging for Conatus (CNAT) Stock Options
Posted on Wednesday March 13, 2019

Conatus (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.


Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
Posted on Wednesday March 13, 2019

The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) will detail results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, and the central reader in the ENCORE-PH trial, will deliver the presentation on Saturday, April 13, at 4:00 p.m. CEST.


Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
Posted on Monday March 11, 2019

Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.